• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023

    3/21/23 11:00:32 AM ET
    $ADC
    $AIZ
    $ALLO
    $ALNY
    Real Estate Investment Trusts
    Real Estate
    Property-Casualty Insurers
    Finance
    Get the next $ADC alert in real time by email

    Upgrades

    For NVIDIA Corp (NASDAQ:NVDA), Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. For the fourth quarter, NVIDIA had an EPS of $0.88, compared to year-ago quarter EPS of $1.32. The stock has a 52-week-high of $289.34 and a 52-week-low of $108.14. At the end of the last trading period, NVIDIA closed at $259.00.

    For Assurant Inc (NYSE:AIZ), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. Assurant earned $3.23 in the fourth quarter, compared to $2.47 in the year-ago quarter. At the moment, the stock has a 52-week-high of $194.04 and a 52-week-low of $104.49. Assurant closed at $111.19 at the end of the last trading period.

    According to Tudor Pickering, the prior rating for Range Resources Corp (NYSE:RRC) was changed from Hold to Buy. For the fourth quarter, Range Resources had an EPS of $1.30, compared to year-ago quarter EPS of $0.96. At the moment, the stock has a 52-week-high of $37.39 and a 52-week-low of $22.61. Range Resources closed at $23.33 at the end of the last trading period.

    For New York Community Bancorp Inc (NYSE:NYCB), DA Davidson upgraded the previous rating of Hold to Buy. For the fourth quarter, New York Community had an EPS of $0.25, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of $11.28 and a 52-week-low of $5.81. At the end of the last trading period, New York Community closed at $8.61.

    For Foot Locker Inc (NYSE:FL), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Foot Locker had an EPS of $0.97, compared to year-ago quarter EPS of $1.67. The stock has a 52-week-high of $47.22 and a 52-week-low of $23.86. At the end of the last trading period, Foot Locker closed at $39.86.

    According to Morgan Stanley, the prior rating for Harley-Davidson Inc (NYSE:HOG) was changed from Equal-Weight to Overweight. Harley-Davidson earned $0.28 in the fourth quarter, compared to $0.15 in the year-ago quarter. The current stock performance of Harley-Davidson shows a 52-week-high of $51.77 and a 52-week-low of $29.82. Moreover, at the end of the last trading period, the closing price was at $37.55.

    For Imperial Oil Ltd (AMEX:IMO), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Imperial Oil earned $2.13 in the fourth quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $58.85 and a 52-week-low of $40.00. At the end of the last trading period, Imperial Oil closed at $46.60.

    Piper Sandler upgraded the previous rating for Wix.com Ltd (NASDAQ:WIX) from Neutral to Overweight. For the fourth quarter, Wix.com had an EPS of $0.61, compared to year-ago quarter EPS of $0.37. The current stock performance of Wix.com shows a 52-week-high of $111.33 and a 52-week-low of $53.12. Moreover, at the end of the last trading period, the closing price was at $88.38.

    Piper Sandler upgraded the previous rating for Vornado Realty Trust (NYSE:VNO) from Underweight to Neutral. Vornado Realty earned $0.72 in the fourth quarter, compared to $0.81 in the year-ago quarter. The current stock performance of Vornado Realty shows a 52-week-high of $47.11 and a 52-week-low of $13.80. Moreover, at the end of the last trading period, the closing price was at $14.38.

    Raymond James upgraded the previous rating for Fleetcor Technologies Inc (NYSE:FLT) from Market Perform to Outperform. Fleetcor Technologies earned $4.04 in the fourth quarter, compared to $3.72 in the year-ago quarter. The stock has a 52-week-high of $265.02 and a 52-week-low of $162.98. At the end of the last trading period, Fleetcor Technologies closed at $199.08.

    For Foot Locker Inc (NYSE:FL), Citigroup upgraded the previous rating of Neutral to Buy. In the fourth quarter, Foot Locker showed an EPS of $0.97, compared to $1.67 from the year-ago quarter. The stock has a 52-week-high of $47.22 and a 52-week-low of $23.86. At the end of the last trading period, Foot Locker closed at $39.86.

    Morgan Stanley upgraded the previous rating for Emerson Electric Co (NYSE:EMR) from Equal-Weight to Overweight. Emerson Electric earned $0.78 in the first quarter, compared to $1.05 in the year-ago quarter. At the moment, the stock has a 52-week-high of $99.99 and a 52-week-low of $72.42. Emerson Electric closed at $82.27 at the end of the last trading period.

    According to Telsey Advisory Group, the prior rating for Foot Locker Inc (NYSE:FL) was changed from Market Perform to Outperform. In the fourth quarter, Foot Locker showed an EPS of $0.97, compared to $1.67 from the year-ago quarter. The current stock performance of Foot Locker shows a 52-week-high of $47.22 and a 52-week-low of $23.86. Moreover, at the end of the last trading period, the closing price was at $39.86.

    According to Morgan Stanley, the prior rating for Meta Platforms Inc (NASDAQ:META) was changed from Equal-Weight to Overweight. Meta Platforms earned $1.76 in the fourth quarter, compared to $3.67 in the year-ago quarter. The current stock performance of Meta Platforms shows a 52-week-high of $205.76 and a 52-week-low of $88.10. Moreover, at the end of the last trading period, the closing price was at $197.81.

    See all analyst ratings upgrades.

    Downgrades

    For Armstrong World Industries Inc (NYSE:AWI), Deutsche Bank downgraded the previous rating of Buy to Hold. For the fourth quarter, Armstrong World Indus had an EPS of $1.08, compared to year-ago quarter EPS of $1.09. The stock has a 52-week-high of $96.51 and a 52-week-low of $67.14. At the end of the last trading period, Armstrong World Indus closed at $69.45.

    According to Maxim Group, the prior rating for Cyclo Therapeutics Inc (NASDAQ:CYTH) was changed from Buy to Hold. Cyclo Therapeutics earned $0.59 in the fourth quarter, compared to $0.34 in the year-ago quarter. The current stock performance of Cyclo Therapeutics shows a 52-week-high of $3.35 and a 52-week-low of $0.86. Moreover, at the end of the last trading period, the closing price was at $0.94.

    For ORIC Pharmaceuticals Inc (NASDAQ:ORIC), Guggenheim downgraded the previous rating of Buy to Neutral. For the fourth quarter, ORIC Pharmaceuticals had an EPS of $0.52, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $7.45 and a 52-week-low of $2.37. At the end of the last trading period, ORIC Pharmaceuticals closed at $4.49.

    Ladenburg Thalmann downgraded the previous rating for Athenex Inc (NASDAQ:ATNX) from Buy to Neutral. Athenex earned $4.28 in the fourth quarter, compared to $6.40 in the year-ago quarter. The current stock performance of Athenex shows a 52-week-high of $24.00 and a 52-week-low of $1.24. Moreover, at the end of the last trading period, the closing price was at $1.26.

    Scotiabank downgraded the previous rating for Suncor Energy Inc (NYSE:SU) from Sector Outperform to Sector Perform. In the fourth quarter, Suncor Energy showed an EPS of $1.35, compared to $0.71 from the year-ago quarter. The stock has a 52-week-high of $42.71 and a 52-week-low of $26.44. At the end of the last trading period, Suncor Energy closed at $29.72.

    Piper Sandler downgraded the previous rating for GoDaddy Inc (NYSE:GDDY) from Overweight to Neutral. In the fourth quarter, GoDaddy showed an EPS of $0.60, compared to $0.52 from the year-ago quarter. The current stock performance of GoDaddy shows a 52-week-high of $88.30 and a 52-week-low of $64.69. Moreover, at the end of the last trading period, the closing price was at $74.40.

    Jefferies downgraded the previous rating for Profound Medical Corp (NASDAQ:PROF) from Buy to Equal-Weight. For the fourth quarter, Profound Medical had an EPS of $0.46, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $13.52 and a 52-week-low of $3.10. Profound Medical closed at $10.16 at the end of the last trading period.

    For Agree Realty Corp (NYSE:ADC), JMP Securities downgraded the previous rating of Market Outperform to Market Perform. For the fourth quarter, Agree Realty had an EPS of $0.95, compared to year-ago quarter EPS of $0.91. The current stock performance of Agree Realty shows a 52-week-high of $80.41 and a 52-week-low of $63.34. Moreover, at the end of the last trading period, the closing price was at $68.84.

    According to Wolfe Research, the prior rating for Oak Street Health Inc (NYSE:OSH) was changed from Outperform to Peer Perform. In the fourth quarter, Oak Street Health showed an EPS of $0.56, compared to $0.62 from the year-ago quarter. The stock has a 52-week-high of $35.84 and a 52-week-low of $13.35. At the end of the last trading period, Oak Street Health closed at $35.70.

    Stifel downgraded the previous rating for Electrameccanica Vehicles Corp Ltd (NASDAQ:SOLO) from Buy to Hold. In the third quarter, Electrameccanica Vehicles showed an EPS of $0.18, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $2.44 and a 52-week-low of $0.57. At the end of the last trading period, Electrameccanica Vehicles closed at $0.58.

    See all analyst ratings downgrades.

    Initiations

    SVB Leerink initiated coverage on Rain Oncology Inc (NASDAQ:RAIN) with an Outperform rating. The price target for Rain Oncology is set to $11.00. For the fourth quarter, Rain Oncology had an EPS of $0.70, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $14.48 and a 52-week-low of $2.18. At the end of the last trading period, Rain Oncology closed at $7.77.

    Bernstein initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:VRTX) with an Outperform rating. The price target for Vertex Pharmaceuticals is set to $344.00. Vertex Pharmaceuticals earned $3.76 in the fourth quarter, compared to $3.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $325.19 and a 52-week-low of $233.14. Vertex Pharmaceuticals closed at $298.95 at the end of the last trading period.

    With an Underperform rating, Bernstein initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN). The price target seems to have been set at $81.00 for Biomarin Pharmaceutical. In the fourth quarter, Biomarin Pharmaceutical showed an EPS of $0.00, compared to $0.32 from the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $117.77 and a 52-week-low of $70.76. Moreover, at the end of the last trading period, the closing price was at $92.34.

    Bernstein initiated coverage on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) with an Outperform rating. The price target for Alnylam Pharmaceuticals is set to $243.00. Alnylam Pharmaceuticals earned $1.39 in the fourth quarter, compared to $1.74 in the year-ago quarter. The stock has a 52-week-high of $242.74 and a 52-week-low of $117.62. At the end of the last trading period, Alnylam Pharmaceuticals closed at $187.52.

    With an Outperform rating, Bernstein initiated coverage on Intellia Therapeutics Inc (NASDAQ:NTLA). The price target seems to have been set at $54.00 for Intellia Therapeutics. For the fourth quarter, Intellia Therapeutics had an EPS of $1.40, compared to year-ago quarter EPS of $1.09. At the moment, the stock has a 52-week-high of $78.58 and a 52-week-low of $32.44. Intellia Therapeutics closed at $38.27 at the end of the last trading period.

    Bernstein initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating. The price target for Beam Therapeutics is set to $37.00. Beam Therapeutics earned $0.54 in the fourth quarter, compared to $0.95 in the year-ago quarter. The current stock performance of Beam Therapeutics shows a 52-week-high of $73.26 and a 52-week-low of $27.90. Moreover, at the end of the last trading period, the closing price was at $32.23.

    With a Market Perform rating, Bernstein initiated coverage on Allogene Therapeutics Inc (NASDAQ:ALLO). The price target seems to have been set at $6.00 for Allogene Therapeutics. For the fourth quarter, Allogene Therapeutics had an EPS of $0.66, compared to year-ago quarter EPS of $0.54. At the moment, the stock has a 52-week-high of $17.48 and a 52-week-low of $5.27. Allogene Therapeutics closed at $5.37 at the end of the last trading period.

    Bernstein initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP) with a Market Perform rating. The price target for CRISPR Therapeutics is set to $44.00. CRISPR Therapeutics earned $1.41 in the fourth quarter, compared to $1.84 in the year-ago quarter. The stock has a 52-week-high of $86.79 and a 52-week-low of $38.94. At the end of the last trading period, CRISPR Therapeutics closed at $44.46.

    Bernstein initiated coverage on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) with a Market Perform rating. The price target for Arrowhead Pharma is set to $27.00. Arrowhead Pharma earned $0.39 in the first quarter, compared to $0.60 in the year-ago quarter. The stock has a 52-week-high of $51.01 and a 52-week-low of $23.09. At the end of the last trading period, Arrowhead Pharma closed at $25.06.

    With an Underperform rating, Bernstein initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS). The price target seems to have been set at $31.00 for Ionis Pharmaceuticals. For the fourth quarter, Ionis Pharmaceuticals had an EPS of $1.18, compared to year-ago quarter EPS of $1.55. The stock has a 52-week-high of $48.82 and a 52-week-low of $31.46. At the end of the last trading period, Ionis Pharmaceuticals closed at $35.60.

    Wells Fargo initiated coverage on Ventyx Biosciences Inc (NASDAQ:VTYX) with an Overweight rating. The price target for Ventyx Biosciences is set to $77.00. Ventyx Biosciences earned $0.59 in the third quarter, compared to $3.17 in the year-ago quarter. The current stock performance of Ventyx Biosciences shows a 52-week-high of $47.25 and a 52-week-low of $9.96. Moreover, at the end of the last trading period, the closing price was at $37.85.

    See all analyst ratings initiations.

    Get the next $ADC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADC
    $AIZ
    $ALLO
    $ALNY

    CompanyDatePrice TargetRatingAnalyst
    Harley-Davidson Inc.
    $HOG
    2/12/2026$30.00 → $25.00Buy
    DA Davidson
    Emerson Electric Company
    $EMR
    2/5/2026$170.00Buy → Hold
    Deutsche Bank
    Meta Platforms Inc.
    $META
    1/29/2026$770.00 → $800.00Overweight
    Barclays
    Meta Platforms Inc.
    $META
    1/29/2026$830.00 → $872.00Buy
    UBS
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Outperform
    Wolfe Research
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Buy
    Roth Capital
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $825.00Overweight
    Analyst
    Meta Platforms Inc.
    $META
    1/29/2026$754.00 → $849.00Overweight
    Wells Fargo
    More analyst ratings

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Patel Naimish bought $49,704 worth of shares (1,508 units at $32.96) (SEC Form 4)

    4 - CRISPR Therapeutics AG (0001674416) (Issuer)

    1/27/26 5:35:15 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Coughenour Peter bought $34,900 worth of shares (500 units at $69.80), increasing direct ownership by 3% to 18,544 units (SEC Form 4)

    4 - AGREE REALTY CORP (0000917251) (Issuer)

    1/13/26 6:59:15 AM ET
    $ADC
    Real Estate Investment Trusts
    Real Estate

    EXECUTIVE CHAIRMAN OF BOARD Agree Richard bought $1,696,080 worth of shares (24,000 units at $70.67) (SEC Form 4)

    4 - AGREE REALTY CORP (0000917251) (Issuer)

    1/12/26 7:09:48 AM ET
    $ADC
    Real Estate Investment Trusts
    Real Estate

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson reiterated coverage on Harley-Davidson with a new price target

    DA Davidson reiterated coverage of Harley-Davidson with a rating of Buy and set a new price target of $25.00 from $30.00 previously

    2/12/26 9:54:13 AM ET
    $HOG
    Motor Vehicles
    Consumer Discretionary

    Emerson downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Emerson from Buy to Hold and set a new price target of $170.00

    2/5/26 6:53:33 AM ET
    $EMR
    Consumer Electronics/Appliances
    Technology

    Barclays reiterated coverage on Meta Platforms with a new price target

    Barclays reiterated coverage of Meta Platforms with a rating of Overweight and set a new price target of $800.00 from $770.00 previously

    1/29/26 9:46:59 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CO & FO Wagner Charles F Jr covered exercise/tax liability with 3,045 shares, decreasing direct ownership by 6% to 48,280 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/12/26 5:10:28 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Reg. & Quality Off. Tatsis Ourania covered exercise/tax liability with 2,140 shares and sold $214,560 worth of shares (466 units at $460.43), decreasing direct ownership by 5% to 51,436 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/12/26 5:08:53 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Chief Patient & Ext Af Off Sachdev Amit covered exercise/tax liability with 2,057 shares, decreasing direct ownership by 3% to 68,941 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    2/12/26 5:06:16 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2025 Results Conference Call Details: Date: Thursday, March 5, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI9b6f

    2/12/26 4:30:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Wix to Announce Fourth Quarter and Full Year 2025 Earnings Results on March 4, 2026

    NEW YORK -- Wix.com Ltd. (NASDAQ:WIX), today announced that it will report its results for the fourth quarter and full year ended December 31, 2025 before the market opens on Wednesday, March 4, 2026. Management will host a conference call and webcast that morning at 8:30 a.m. ET to answer questions about the Company's financial results. Prior to the conference call and webcast, Wix will issue a press release reporting these results along with a shareholder update and additional materials at https://investors.wix.com/.  What:Wix Fourth Quarter and Full Year 2025 Results Conference CallWhen: Wednesday, March 4, 2026Time:8:30 a.m. ET Registration: https://edge.media-server.com/mmc/p/4zs5pwq2 R

    2/12/26 4:30:00 PM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Meta Announces Quarterly Cash Dividend

    MENLO PARK, Calif., Feb. 12, 2026 /PRNewswire/ -- The Meta Platforms, Inc. (NASDAQ:META) board of directors today declared a quarterly cash dividend of $0.525 per share of the company's outstanding Class A common stock and Class B common stock, payable on March 26, 2026 to stockholders of record as of the close of business on March 16, 2026. About MetaMeta is building the future of human connection, powered by artificial intelligence and immersive technologies. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram, and WhatsApp furth

    2/12/26 4:05:00 PM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    $ADC
    $AIZ
    $ALLO
    $ALNY
    SEC Filings

    View All

    SEC Form 10-K filed by CRISPR Therapeutics AG

    10-K - CRISPR Therapeutics AG (0001674416) (Filer)

    2/12/26 4:59:04 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Profound Medical Corp. (0001628808) (Filer)

    2/12/26 4:35:35 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    CRISPR Therapeutics AG filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CRISPR Therapeutics AG (0001674416) (Filer)

    2/12/26 4:35:28 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADC
    $AIZ
    $ALLO
    $ALNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Leadership Updates

    Live Leadership Updates

    View All

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Financials

    Live finance-specific insights

    View All

    Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2025 Results Conference Call Details: Date: Thursday, March 5, 2026 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI9b6f

    2/12/26 4:30:00 PM ET
    $PROF
    Medical/Dental Instruments
    Health Care

    Wix to Announce Fourth Quarter and Full Year 2025 Earnings Results on March 4, 2026

    NEW YORK -- Wix.com Ltd. (NASDAQ:WIX), today announced that it will report its results for the fourth quarter and full year ended December 31, 2025 before the market opens on Wednesday, March 4, 2026. Management will host a conference call and webcast that morning at 8:30 a.m. ET to answer questions about the Company's financial results. Prior to the conference call and webcast, Wix will issue a press release reporting these results along with a shareholder update and additional materials at https://investors.wix.com/.  What:Wix Fourth Quarter and Full Year 2025 Results Conference CallWhen: Wednesday, March 4, 2026Time:8:30 a.m. ET Registration: https://edge.media-server.com/mmc/p/4zs5pwq2 R

    2/12/26 4:30:00 PM ET
    $WIX
    Computer Software: Programming Data Processing
    Technology

    Meta Announces Quarterly Cash Dividend

    MENLO PARK, Calif., Feb. 12, 2026 /PRNewswire/ -- The Meta Platforms, Inc. (NASDAQ:META) board of directors today declared a quarterly cash dividend of $0.525 per share of the company's outstanding Class A common stock and Class B common stock, payable on March 26, 2026 to stockholders of record as of the close of business on March 16, 2026. About MetaMeta is building the future of human connection, powered by artificial intelligence and immersive technologies. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram, and WhatsApp furth

    2/12/26 4:05:00 PM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    $ADC
    $AIZ
    $ALLO
    $ALNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Assurant Inc.

    SC 13G/A - ASSURANT, INC. (0001267238) (Subject)

    12/9/24 6:04:05 AM ET
    $AIZ
    Property-Casualty Insurers
    Finance

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care